Novo A/S
Novo A/S is the holding company of the Novo Group, wholly-owned by the Novo Nordisk Foundation.
Novo A/S is the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.
Novo A/S’ objective is to manage the...Founded in 1999
Homepage: http://www.novo.dk/
HQ
Hellerup Tuborg Havnevej 19Hellerup
DNK
Novo A/S at CrunchBase
Heath Lukatch Partner
Tiba Aynechi Venture Group
Past
June, 2013
Novo A/S invested $41M in Akebia Therapeutics as a Series C round
May, 2013
Novo A/S invested $175M in Ophthotech as a Series C round
Novo A/S invested $55.4M in Symphogen as private_equity round
March, 2013
Novo A/S invested $60M in PTC Therapeutics as unattributed round
September, 2012
Novo A/S invested $7.6M in Karus Therapeutics as a Series B round
July, 2012
Novo A/S invested $30M in PTC Therapeutics as unattributed round
June, 2012
Novo A/S invested $12M in Santaris Pharma as unattributed round
April, 2012
Novo A/S invested $20M in Inogen as unattributed round
Novo A/S invested $25M in AlloCure as a Series B round
March, 2012
Novo A/S invested $28M in Tarsa Therapeutics as a Series B round
February, 2012
Novo A/S invested $12.5M in Altheos as a Series A round
September, 2011
Novo A/S invested $20M in Orphazyme as a Series A round
August, 2011
Novo A/S invested $12.7M in KalVista Pharmaceuticals as a Series A round
July, 2011
Novo A/S invested $6.5M in Vantia Therapeutics as a Series B round
February, 2011
Novo A/S invested $15.7M in HTG Molecular Diagnostics as a Series D round
Novo A/S invested $15.7M in High Throughput Genomics as a Series D round
Novo A/S invested $135.4M in Symphogen as a Series F round
Novo A/S invested unknown amount in Orphazyme as seed round
January, 2011
Novo A/S invested $135M in Symphogen as unattributed round
October, 2010
Novo A/S invested $20M in ProteinSimple as a Series F round
Novo A/S invested $30M in Synosia Therapeutics as a Series C round
September, 2010
Novo A/S invested $31M in Tobira Therapeutics as a Series B round
July, 2010
Novo A/S invested $78M in Reata Pharmaceuticals as unattributed round
May, 2010
Novo A/S invested $16.9M in Logical Therapeutics as a Series C round
Novo A/S invested unknown amount in Nanoference as unattributed round
April, 2010
Novo A/S invested $99M in Archimedes Pharma as a Series C round
Novo A/S invested $20M in Altheos as a Series A round
December, 2009
Novo A/S invested $50M in PTC Therapeutics as a Series E round
Novo A/S invested $30M in Ophthotech as a Series B round
Novo A/S invested $4M in ProteinSimple as unattributed round
October, 2009
Novo A/S invested $50M in Lux Biosciences as a Series B round
April, 2009
Novo A/S invested $10M in ProteinSimple as a Series C round
November, 2007
Novo A/S invested $4.1M in f-star Biotech as a Series A round
Novo A/S invested $33M in AnaptysBio as a Series B round
January, 2007
Novo A/S invested $32.5M in Synosia Therapeutics as unattributed round
June, 2006
Novo A/S invested $16M in MediQuest Therapeutics as a Series A round
May, 2006
Novo A/S invested $4.1M in Celltrix as unattributed round
January, 2006
Novo A/S invested $25M in Symphogen as a Series D round
December, 2005
Novo A/S invested $67M in Light Sciences Oncology as a Series A round
November, 2005
Novo A/S invested $26.6M in PTC Therapeutics as unattributed round
1999
Novo A/S was founded in 1999